In particular, treatment with PBCAR0191, an anti-CD19 CAR-T product in which endogenous TCR is disrupted by gene editing to prevent GvHD, together with an intensified lymphodepletion, has shown clinical benefit in the majority of NHL patients, yielding high rates of overall and complete response with promising activity in both CD19 CAR naïve subjects and those who progressed following auto-CD19 CAR therapy (56, 57). The gene discussed is CD19; the disease is graft versus host disease.